Clinical trials

Knee osteoarthritis usually occurs first in the medial (inside) portion of the knee joint. Unlike total knee replacement that removes all the knee joint surfaces, a unicondylar or partial knee replacement replaces only one part of the knee joint. Some advantages of having a partial knee replacement are that it removes less bone and cartilage, may require a shorter hospital stay, may be less painful, may enable a more rapid recovery, and may provide more natural motion when compared to a total knee replacement.

The Uniglide™ mobile bearing unicondylar knee system is not available for commercial use in the United States and, like other mobile bearing knee replacements, it requires clinical data for submission to the Food and Drug Administration (FDA). Surgeons throughout the United States are participating in an Investigational Device Exemption (IDE) research study, sponsored by Corin USA, to collect clinical data and X-rays on each patient for a total of two years. The FDA will use the data collected during this clinical study as a part of the approval process for the United States.

If you are between the ages of 40 and 80 with osteoarthritis of one or both knees and want to learn more about participating in this FDA-regulated study*, please consult one of our investigators in your area (click here for a list of locations) or call Diana Martone at Corin USA on  +1 813 977 4469.

To find out if you meet the general requirements for this study*, click here. 

 

*A licensed orthopaedic surgeon participating in this study will make the final determination of your eligibility. Please refer to the list of investigators on the study sites page for their contact information.